Case Details

Year Initiated/Committed

2016

Settlement Amount

n/a

Court

U.S. District Court for the District Court of Pennsylvania

Docket Number

16-5073

Lead State

AK, AL, AR, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, KS, KY, LA, MA, MD, ME, MI, MN, MO, MP, MS, NC, NE, NH, NM, NY, OH, OK, OR, PA, RI, SC, TN, UT, VA, VT, WA, WI, WV

Participating States

AK, AL, AR, CA, CO, CT, DC, DE, FL, GA, GU, HI, IA, ID, IL, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, NE, NH, NM, NY, OH, OK, OR, PA, RI, SC, TN, UT, VA, VT, WA, WI, WV

Defendant(s)

Indivior Inc. f/k/a/ Reckitt Benckiser Pharmaceuticals, In.; Reckitt Benckiser Healthcare (UK) Ltd.; Indivior PLC f/d/a/ Reckitt Benckiser Group plc; Monosol RX. LLC

Case Description

Plaintiff states alleged that the makers of Suboxone, a drug used to treat opioid addiction, engaged in a scheme to block generic competitors and raise prices. Specifically, they are conspiring to wtich Suboxone from a tablet version to a flim in order to prevent or delay generic entry. The states allege that the manufacturers engaged in “product hopping” in which a company makes slight changes to its product to extend patent protections and prvent generic alternatives. The complaint was filed under seal.